
    
      This is a Phase 2, multicenter, randomized, single-blind, placebo-controlled cross-over study
      in patients with refractory PBH.

      Participants will be randomized and assigned in a 1:1 ratio to one of two treatment arms. All
      participants will receive 2 dosing regimens of exendin 9-39 and matching placebo
      self-administered via subcutaneous (SC) injection.

      Participants will undergo in-clinic mixed meal tolerance test (MMTT) provocation with
      concomitant blood draws and symptom assessments.
    
  